How does pindolol improve antidepressant action?

Trends in Pharmacological Sciences

Volumn 22, Issue 5, 2001, Pages 224-228

  Artigas, Francesc ^a   Celada, Pau ^a   Laruelle, Marc ^b   Adell, Albert ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; BETA ADRENERGIC RECEPTOR; CLOMIPRAMINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; PAROXETINE; PINDOLOL; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN UPTAKE INHIBITOR; TRAZODONE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR OCCUPANCY; REVIEW; SEROTONIN RELEASE;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; ANTIDEPRESSIVE AGENTS; HUMANS; PINDOLOL; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS;

EID: 0035336925     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-6147(00)01682-5     Document Type: Review

References (53)

1. Alternative prospections of mortality and disability by cause 1990-2020: Global Burden of Disease Study
2. SSRIs: Where now, where next?
3. 1A antagonists
4. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat
5. 5-HT and antidepressants: New views from microdialysis studies
6. Current advances and trends in the treatment of depression
7. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors
8. Randomised, double-blind, placebo-controlled trial of pindolol in combination withfluoxetine antidepressant treatment
9. Paroxetine and pindolol: A randomized trial of 5-HT autoreceptor blockade in the reduction of antidepressant latency
10. How long should pindolol be associated with paroxetine to improve the antidepressant response?
11. Effect of pindolol on onset of action of paroxetine in the treatment of major depression: Intermediate analysis of a double-blind, placebo-controlled trial
12. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: A controlled study
13. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial
14. Does the addition of pindolol accelerate the response to electroconvulsive therapy in patients with major depression? A double-blind, placebo-controlled pilot study
15. Efficacy of treatment with trazodone in combination with pindolol or fluoxetine in major depression
16. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance
17. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression - A placebo-controlled trial
18. Pindolol augmentation of treatment-resistant depressed patients
19. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors
20. 11C]WAY 100635 and positron emission tomography in humans
21. 1A receptors measured in vivo using small animal positron emission tomography with carbon-11 labeled WAY 100635
22. 1A receptors in vivo and in vitro. Implications for antidepressant therapy
23. 1A receptor ligands to pre- and postsynaptic receptors by (-)pindolol. A comparative study in rodent, primate and human brain
24. 1A receptors in human and rat brain
25. 1A receptors in rat brain membranes
26. 1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: Single-unit study in unanesthetized, unrestrained rats
27. Modulation of the firing activity of rat serotonin and noradrenaline neurons by (±)pindolol
28. 1A receptors in the rat brain
29. 1A) receptors
30. 1A autoreceptor in vivo
31. Pindolol suppresses serotonergic neuronal activity and does not block the inhibition of 5-HT neurons produced by 8-hydroxy-2-(di-n-propylamino)tetralin in awake cats
32. 1A agonist potential of pindolol: Electrophysiologic studies in the dorsal raphe nucleus and hippocampus
33. 1A receptor agonists and antagonists: A comparison to adrenergic and dopaminergic neurons in rats
34. 1A antagonist, does not reverse the inhibition of 5-HT neuronal activity induced by fluoxetine in awake cats: Comparison to WAY-100635
35. 1A autoreceptors in the action of selective serotonin reuptake inhibitors
36. Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine
37. 1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: The mechanism action of (±)pindolol
38. Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: A microdialysis study
39. Increased prescribing of antidepressants subsequent to β-blocker therapy
40. Pindolol and major affective disorders: A three-year follow-up study of 30 385 patients
41. 1B receptors
42. The effect of ipsapirone and S(-)-pindolol on dopamine release in rat striatum and nucleus accumbens
43. Effect of reboxetine augmentation in SSRI resistant patients
44. Antagonism of the stimulus effects of yohimbine and 8-hydroxydipropylaminotetralin
45. 2 agonist radioligand
46. 1 recognition sites
47. 1D receptor in rat and human brain
48. 1 receptor subtype coupled to the inhibition of adenylate cyclase
49. β-adrenoceptor blocking agents recognize a subpopulation of serotonin receptors in brain
50. 1B receptors
51. 1B receptors of rat brain: Selectivity of β-adrenergic agents
52. 5-HT receptors: Subtypes and second messengers
53. 1D receptor: A progress review